Dr. Neil Shore recently contributed to innovation in prostate cancer treatment by authoring a scientific article about the results of a recent clinical trial. The results were published in the Journal of Urology in August. The providers at Atlantic Urology Specialists believe in the importance of clinical trials in advancing medicine, and Dr. Shore is no exception.
The study, called the Apa-RP Study, examined a treatment protocol for men who have been previously treated for high-risk localized prostate cancer. These men are at a higher risk of prostate cancer returning, which is initially detected by a rise in PSA levels. The treatment protocol involved the use of a drug called apalutamide in conjunction with androgen deprivation therapy.
The results of the trial are promising and may become an option for men who are at high risk of prostate cancer recurrence. Read the study here.
This is a great example of the important work Dr. Shore and the providers at Atlantic Urology Specialists do to make sure their patients, and patients in the future, have access to the most effective treatments.
